These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37326326)

  • 1. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
    Ghany MG; Buti M; Lampertico P; Lee HM;
    Hepatology; 2023 Nov; 78(5):1654-1673. PubMed ID: 37326326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
    Ghany MG; Buti M; Lampertico P; Lee HM;
    J Hepatol; 2023 Nov; 79(5):1254-1269. PubMed ID: 37377088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
    Cornberg M; Lok AS; Terrault NA; Zoulim F;
    J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
    Cornberg M; Lok AS; Terrault NA; Zoulim F;
    Hepatology; 2019 Nov; ():. PubMed ID: 31713892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
    J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
    Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Janssen HLA; Hou J; Asselah T; Chan HLY; Zoulim F; Tanaka Y; Janczewska E; Nahass RG; Bourgeois S; Buti M; Lampertico P; Lenz O; Verbinnen T; Vandenbossche J; Talloen W; Kalmeijer R; Beumont M; Biermer M; Shukla U
    Gut; 2023 Jul; 72(7):1385-1398. PubMed ID: 36697207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
    Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
    J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
    J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Bian D; Zhao J; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2023 Apr; 30(4):303-309. PubMed ID: 36533536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
    Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
    Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.